by Bhami Research Laboratory | Nov 2, 2021 | News
Using only 2 GRAS excipients, BRL has achieved concentrations of over 250mg/mL with viscosities less than 20cP. Stability data – both in-house and from third party CROs, shows that this high-concentration, low-viscosity formulation of Trastuzumab is physically,...
by Bhami Research Laboratory | Nov 2, 2021 | News
With this new patented technology that holds great potential as a ‘Platform’ technology, BRL aims to help large and small biopharmaceutical companies achieve syringeable viscosities for high-concentration protein biologics like monoclonal antibodies. This...
by Bhami Research Laboratory | Nov 2, 2021 | News
With multiple patents, publications and grants under his belt, Dr. Bhami Shenoy is one of the foremost scientists in the field of protein biologics in the world. With over 11 years at Altus Pharmaceuticals and 5 years at ProCrysta in the USA, Dr. Bhami decided to give...
by Bhami Research Laboratory | Nov 2, 2021 | News
In a recent study conducted by BRL, the purity and overall characteristics of trastuzumab were compared between Protein A purification (conventional method) and crystallization (BRL’s Technology). As a result, comparable purity was observed between the two in...
by Bhami Research Laboratory | Nov 2, 2021 | News
50-80% of protein manufacturing costs are incurred during the purification and subsequent steps especially Protein A chromatography. This is cost intensive process and adds significant amount of time to the manufacturing process. BRL’s technology allows for...
by Bhami Research Laboratory | Nov 2, 2021 | News
High-dosage biologics like monoclonal antibodies (mAbs) have significant challenges due to inherent aggregation, instability and difficulty of administration in high concentrations. Over 80% of these biologics are administered intravenously over long periods of time....
